Market News AIOpen the app

BEAT stock news · HeartBeam

Stories about HeartBeam (BEAT) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for BEAT

Follow HeartBeam (BEAT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BEAT
Free on the App Store and Google Play, or on the web.
  1. Oct 6, 2026, 8:15 AM ET · Market

    12 health care stocks are changing in price before the market opens on Tuesday.

    Neutral

    HeartBeam's shares fell about 8% to $0.60 per share before Tuesday's market opened. The article gives no company update or reason for the drop, so it does not change the business outlook.

  2. Oct 5, 2026, 1:54 PM ET · Trial

    HeartBeam has been approved by the FDA for its home device that detects heart attacks.

    Good for BEAT

    HeartBeam received a special FDA designation that speeds regulator review of its at-home heart tool. The company still needs a larger study and clearance for heart-attack use.

  3. Oct 5, 2026, 1:09 PM ET · Market

    12 health care stocks are changing a lot during Monday's trading.

    Neutral

    HeartBeam shares rose 70.5% during Monday’s session, but the article gives no reason or company update. The price move alone does not change its business outlook.

  4. Oct 5, 2026, 1:08 PM ET · Market

    12 health care companies saw big changes during Monday's trading.

    Neutral

    HeartBeam's shares rose 71% during Monday's session, but the story gives no company news to explain the move. It does not change the outlook for HeartBeam.

  5. Oct 5, 2026, 12:49 PM ET · Market

    The Dow went up by 100 points, but the ISM Services PMI dropped in September.

    Good for BEAT

    HeartBeam received FDA breakthrough device status for its heart attack assessment product. This supports its development, but it is not product approval.

  6. Oct 5, 2026, 9:50 AM ET · Market

    U.S. stocks had mixed results, with the Nasdaq up more than 50 points.

    Good for BEAT

    HeartBeam received FDA breakthrough device designation for heart attack assessment. This is a helpful step for its device, though the story does not report approval or sales.

  7. Aug 13, 2026, 5:45 PM ET · Results

    HeartBeam Delivers Q2 2026 Financial Results: Complete Earnings Call Transcript Available.

    Good for BEAT

    HeartBeam's Q2 2026 earnings report reveals a 7% decrease in operating cash outflow and a significant step towards FDA approval for its heart attack detection technology. This progress, along with positive feedback from initial commercial launches, positions the company favorably in the healthcare market.